论文部分内容阅读
本刊讯1月31日,蓝丰生化发布2014年业绩预告公告,预计2014年1月1日到2014年12月31日期间,公司归属于上市公司股东的净利润亏损2800~3800万元,去年同期盈利2110万元。据公告披露,业绩下滑的主要原因有两个:一是公司产品利润下降。除草剂环嗪酮及杀菌剂多菌灵,2014年度较去年同期销量下滑明显,毛利率下降,且2014年第四季度销售情况未有好转。其二是公司与杭州醒治化工有限公司合同纠纷案,一审判决公
On January 31, Lanfeng Biochemical released the announcement of 2014 performance forecast. It is expected that from January 1, 2014 to December 31, 2014, the net profit loss of the Company attributable to shareholders of the listed company will be 2800 ~ 3800 million yuan, Last year, a profit of 21.1 million yuan. According to the announcement disclosed that there are two main reasons for the decline in performance: First, corporate profits declined. Herbicide hexazinone and bactericide, carbendazim, showed a significant decrease in sales volume in 2014 as compared with the same period of last year. The gross profit margin dropped and the sales in the fourth quarter of 2014 were not improved. The second is the company and Hangzhou Awaking Chemical Co., Ltd. contract dispute case, the first instance verdict